Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Spectrum

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Spectrum
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
From Research to Practice

Palliative and End-of-Life Care: Vital Aspects of Holistic Diabetes Care of Older People With Diabetes

  1. Trisha Lynette Dunning
  1. Centre for Quality and Patient Safety Research, Barwon Health Partnership, School of Nursing and Midwifery, Deakin University, Geelong, Australia
  1. Corresponding author: Trisha Lynette Dunning, trisha.dunning{at}deakin.edu.au
Diabetes Spectrum 2020 Aug; 33(3): 246-254. https://doi.org/10.2337/ds20-0014
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

Palliative and end-of-life care and advance care planning are important components of holistic diabetes management, especially for older people with a long duration of diabetes and comorbidities who experience unpleasant symptoms and remediable suffering. Many diabetes clinicians do not have conversations about advance care planning with people with diabetes, often because they are reluctant to discuss these issues and are not familiar with palliative care. This article outlines palliative, terminal, and end-of-life care for older people with type 1 or type 2 diabetes and suggests when to consider changing the focus on tight blood glucose control to a focus on safety and comfort. It proposes strategies to incorporate palliative and end-of-life care into personalized holistic diabetes care, determined with older people with diabetes and their families through shared decision-making.

People with type 1 or type 2 diabetes grow old, but many have a shorter life expectancy than the general population (1). Many older adults with diabetes have long duration of diabetes, diabetes complications, frailty, and cognitive changes or dementia. They are prone to unpleasant symptoms associated with these conditions and to hypoglycemia and hyperglycemia, which cause significant morbidity and mortality (2). Consequently, they often have unmet physical, mental, spiritual, and emotional needs that compound pain and other symptoms. The pain and suffering frequently go unrecognized and untreated.

Diabetes was in the top 10 causes of death globally in 2016; some of the other top 10 causes of death, such as ischemic heart disease (number one), are associated with diabetes (3). Approximately 67% of these deaths occur in people ≥60 years of age (3). However, chronological age does not equate to an individual’s disease status, functional status, life expectancy, or care needs (4,5), all of which are influenced more by the individual’s genetic inheritance and biological age. Many older people with diabetes have three or more comorbidities that reduce life expectancy (e.g., cardiovascular disease, cognitive changes, dementia, renal disease, various degrees of frailty, and cancer [6–8]). Significantly, diabetes complications can be present before type 2 diabetes is diagnosed (4,6).

Several medicines are usually required to manage diabetes and its associated comorbidities. Consequently, polypharmacy is common, albeit often necessary, and adds to the burden of lifelong self-management. Self-management encompasses eating a healthy diet, undertaking physical activity, monitoring blood glucose, and recognizing and managing hyperglycemia and hypoglycemia.

Hypoglycemia unawareness is common in older people with type 1 diabetes and some people with type 2 diabetes. Thus, many older people on insulin and sulfonylurea glucose-lowering medications are at risk for significant harm from tight blood glucose control (9).

People with diabetes usually follow a chronic disease trajectory in which slow disease progression and unpredictable exacerbations of the underlying disease processes occur and can lead to emergency department presentations or hospital admissions (10–12). The exacerbations become more frequent over time and result in increasing frailty and other geriatric syndromes that cause emotional distress, further functional decline, slow recovery, and eventual death.

Consequently, many older people with diabetes develop significant cumulative burdens related to their disease, treatment, and self-care, which make focusing on tight blood glucose control unrealistic and unsafe as they reach older age (2,5,13). Therefore, the focus of care needs to gradually change to a palliative approach that involves determining a safe blood glucose range to both prevent glucose variability and glycemic emergencies and manage the burdens and harms that affect comfort, cause suffering, and reduce quality of life (5,13). That is, the focus shifts to identifying and prioritizing interventions likely to be beneficial and stopping those unlikely to be beneficial in the individual’s remaining lifetime. This strategy might include not commencing interventions that delay death but increase suffering (14,15). Such decisions can be challenging for clinicians accustomed to focusing on active and curative care.

We can still learn from Hippocrates, who described the basic philosophy of all care in his Book of Prognosis: “First, do no harm, observe all, evaluate honestly, prognosticate when you can, counsel the patient about what to expect in the course of their illness, especially when the prognosis is poor, and when it comes to therapeutics, assist nature” (16). Hippocrates also described prognostic indicators and advocated for effective communication between the patient and the physician (16). The philosophy is still relevant to modern palliative care.

Palliative, Terminal, and End-of Life Care

The three terms, palliative, terminal, and end-of-life care, are defined in Table 1, along with some suggestions for when to implement palliative and end-of-life care and some implementation strategies that may be used.

View this table:
  • View inline
  • View popup
TABLE 1

Palliative, Terminal, and End-of-Life Care and Suggestions Regarding When and How to Implement Each

Historically, palliative care was associated with hospice and cancer care at the end of life and did not include curative care. Consequently, many clinicians equate palliative care with terminal care (17) and regard death as a treatment failure. Significantly, though, palliative care can be commenced at any time and can be used with a patient’s “usual” care (18,19). Generally, the earlier palliative care is implemented, the greater the benefit (18–20).

Many diabetes clinicians are not familiar with palliative and end-of-life care or comfortable discussing these issues with people with diabetes and their families. The National Coalition for Hospice and Palliative Care has noted that palliative care is the responsibility of all clinicians—not the sole preserve of palliative care specialists (20). The coalition’s guidelines recommend that service providers and clinicians integrate palliative care into the care plans of people with serious illnesses, including proactively discussing end-of-life care (20). However, clinicians often wait until a patient or patient’s family raises the issue. Likewise, the patient and family often wait until the doctor initiates such conversations. Consequently, nobody raises the issue, and conversations about palliative and end-of-life care do not occur (21).

Optimal palliative care requires many conversations with individuals about their values and care goals as their health status changes. Thus, communication and advance care planning is a continuing process and a key aspect of palliative care. However, many clinicians find it difficult to discuss these issues because of inadequate skills and training, time constraints, fear of conflict (17), and the challenge of prognostication. Clinicians’ intuitive prognostication can be inaccurate, and prediction tools are not particularly helpful (21).

Palliative care can be delivered in a person’s home, in a hospice, or in the hospital (Table 2). Many people prefer to die at home, but most do not actually do so (18,22).

View this table:
  • View inline
  • View popup
TABLE 2

Palliative and End-of-Life Care Settings and Issues to Be Considered in Each

Managing Diabetes During Transition to End of Life

Two guidelines and one article focus on palliative and end-of-life diabetes care (5,13,23), although the topic is also included within several other general guidelines. Most of the guidance in this area is based on low-level evidence and expert consensus; however, it makes clinical sense, is consistent with palliative care guidelines, and focuses on personalised care. Table 1 defines end-of-life care and outlines care strategies for people with diabetes requiring terminal and end-of-life care.

As previously noted, the care focus must gradually shift from tight blood glucose control to comfort and symptom control for patients with either type 1 or type 2 diabetes (5,8,12,13,23). Preventing hypoglycemia and hyperglycemia and their associated uncomfortable symptoms is essential. Both states are associated with increased risks of death, although hypoglycemia might be a marker, but not a cause, of poor outcomes, at least for people hospitalized after myocardial infarction (24). It might also be important to reduce glucose variability, especially during disease exacerbations (25).

Glucose-lowering medication doses may need to be reduced or different formulations used, while also simplifying the regimen as much as possible. Glucose-lowering medications are used to prevent hyperglycemia and its symptoms and reduce the risk of diabetic ketoacidosis or hyperglycemic hyperosmolar state. That is, they can be used with a palliative intent for symptom control in older people with type 1 or type 2 diabetes rather than to achieve tight blood glucose control. Preventing diabetes complications is largely irrelevant in older people approaching the end of life.

A generally accepted safe blood glucose range is 6–11 mmol/L (108–198 mg/dL) (13,23), although some Australian guidelines recommend 6–15 mmol/L (108–270 mg/dL) (4,5). Sliding-scale insulin (i.e., hyperglycemia correction doses) should not be used alone but may be a useful add-on to a basal-bolus insulin regimen. Sliding-scale insulin is more likely to cause glucose variability and hypoglycemia that can lead to a hospital admission (5,13,25) and is a predictor of death in critical illness (25). Transitioning to a basal-bolus insulin regimen can help avoid hypoglycemia and reduce the care burden on the patient, family, and care staff (5,13).

Usual prescribing guidelines and algorithms should be used to manage all classes of medications and individual drugs within each class. However, the following cautions apply with regard to glucose-lowering medicines (5,13,23).

  • Metformin is generally safe but may be contraindicated in people with gastrointestinal cancers and other gastrointestinal problems.

  • Sulfonylureas increase the risk of hypoglycemia, especially in people with low oral intake and/or liver disease. This risk is further increased if insulin is used with a sulfonylurea.

  • Pioglitazone may be contraindicated in people with or at risk for bladder cancer.

  • Dipeptidyl peptidase‐4 (DPP-4) inhibitors have low hypoglycemia risk alone but can increase the risk of hypoglycemia if used with sulfonylureas. Some DDP-4 inhibitors should be used with caution or stopped in people with renal disease.

  • Glucagon-like peptide 1 receptor agonists have low or no hypoglycemia risk but should be stopped in patients who develop pancreatitis or abdominal pain.

  • Sodium–glucose cotransporter 2 inhibitors have a low hypoglycemia risk. They should be stopped when patients develop an intercurrent illness or require surgery because of the risk of dehydration and associated hyperosmolar or ketoacidotic states. Ketone testing should be started if it is not already used.

Blood glucose monitoring can be a useful guide to the underlying cause of symptoms such as nausea, headache, and urinary frequency in people with type 1 and type 2 diabetes (26). Our research shows that people in the last stages of life value blood glucose monitoring because it enables the identification and treatment of the causes of some symptoms (27). It is also useful when corticosteroids are used (5,13,23). Monitoring frequency should be tailored to the action profile of the glucose-lowering medications and the individual’s food intake and activity levels. Food intake can be erratic for a range of reasons, including dementia, dysphagia, changed taste sensation resulting from aging or chemotherapy, and dissatisfaction with the food served in hospitals, aged care homes, or long-term care facilities.

Advance Care Planning

The terms and processes used for advance care planning vary around the world to accommodate legislation, language, and religious and cultural imperatives. However, the purpose remains constant: to ensure that the individual has a good death. Diabetes clinicians are ideally placed to help older people with diabetes clarify their values, preferences, and care goals and to document them in an advance care plan because diabetes care requires regular follow-up appointments and screenings for complications.

Advance care planning involves people with diabetes discussing their preferred future care with clinicians and family members while they can make autonomous decisions (informed consent). Documenting the person’s values—the things that give meaning and purpose to the person’s life—is extremely important. Values are a useful guide later on to the type of care a person would choose to achieve quality of life.

People value having some control over the way they die, being free from pain, and having time to complete important business and to say goodbye to family and friends (5,22,27). For example, achieving personal goals such as attending a grandchild’s wedding may be more important than living a longer life (28). Thus, care should support people in achieving their goals, when possible. Significantly, people who document their values and goals and instructions about the care they want or do not want are more likely to receive care consistent with their preferences. Discrepancies between the values of patients and clinicians are well documented (29). For example, clinicians underestimate the burden of symptom severity compared with patient ratings, and many tools that measure such outcomes do not adequately capture the patients’ perspective (28,29).

Advance care plans are guides to and decision aids for determining an individual’s values and care goals. They can help clinicians and patient surrogates or caregivers make difficult treatment decisions when patients cannot decide for themselves, provided they meet legal requirements (e.g., they are signed and witnessed) (21,30). As previously noted, clinicians often miss opportunities to initiate conversations to help people make such plans (31). Indeed, some such conversations occur during rapid response or medical emergency interventions (32), which is clearly not an appropriate time to make decisions about emotion-laden issues.

Some clinicians believe that people do not want to discuss dying and advance care planning, and in some cases, this is true. Generally, however, people are more open to such discussions when they have disabilities and illnesses (33). Our research shows that people with diabetes want to discuss their end-of-life care in their last months of life, but they are often reluctant to initiate discussions because they worry about upsetting their clinicians and because clinicians do not ask them (27,34).

Most patients, caregivers, and clinicians want some idea of prognosis when a patient’s condition deteriorates, and not considering prognosis could result in lower-quality care (35). Prognostication, like deciding benefits and harms, is challenging, however. As Hippocrates said, “It appears to be a most excellent thing for the physician to cultivate prognosis” (16).

Palliative and diabetes prognostic tools that can help clinicians “cultivate prognosis” include the Supportive and Palliative Care Indicators Tool (36) and The Gold Standards Framework Prognostic Indicator (37). These tools can help clinicians identify people who would benefit from palliative care. Clinicians can then provide palliative care themselves or refer patients to specialist palliative care services (5), as well as help the identified patients develop or update their advance care plans, if necessary.

What Do People With Diabetes and Their Families Think?

People with diabetes and their families need to make many complex decisions about their diabetes self-care on a daily basis and when considering palliative and end-of-life care. We interviewed older people with type 1 or type 2 diabetes receiving palliative care, their family carers, and palliative care clinicians when we developed the Guidelines for Managing Diabetes at the End of Life (38). Our findings suggest that people with diabetes and their families consider blood glucose testing to be a useful guide to identifying hypoglycemia and hyperglycemia and enables early recognition and treatment of their associated unpleasant symptoms (27). Blood glucose monitoring is also a familiar routine for many people with type 1 diabetes during a time of change.

We also found that most people wanted to continue taking their glucose-lowering medications until the terminal stage to manage hyperglycemia, which can cause confusion, frequent urination, and tiredness and compound other symptoms such as delirium, all of which cause discomfort and reduce quality of life. They also wanted to avoid hypoglycemia because of its associated loss of control and symptom burden (27,34).

Patients’ family members, mostly spouses, were concerned about having to undertake diabetes tasks such as blood glucose monitoring and insulin administration when their relative could no longer manage (27). They said they had not received education about how to do these tasks and worried they could accidently give the wrong insulin dose and hasten death. Underlying this concern was the risk of unintentionally causing death and being accused of murdering their relative.

Documenting an advance care plan is time-consuming and distressing for individuals, their family members, and clinicians. However, advance care planning specialists, when available, can help reduce the stress. Helping people create a life narrative enables them to find meaning and purpose, develop a sense of coherence, and maintain their identity (personhood), self-esteem, and coping capacity as they prepare for their end of life (39).

Summary

It is important to understand individuals’ journey with diabetes and changing care needs as they transition through older age and toward the end of life. Helping people with diabetes cope with a life-limiting illness is a privilege. It is also an ethical responsibility, given the current focus on autonomy, patient engagement, and personalized care. Generally, a more flexible approach to food choices, blood glucose monitoring, and the blood glucose target range is preferable to achieving tight glycemic control. The specifics of care must be decided with individuals and their families. Prognostication is challenging and contributes to moral distress. Thus, clinicians and people with diabetes need to know how to or get help to manage uncertainty and cope with such distress.

Documented values, care goals, and preferences can help reduce uncertainty and aid decision-making when older people cannot decide for themselves and can be used in conjunction with guidelines such as the Gold Standards Framework (37). Such plans do not need to be completed all at once; starting early allows people time to think through the issues involved. Once a plan is documented, it should be reviewed regularly because peoples’ goals of care can change, although their values tend to remain relatively constant. Significantly, living as long as possible is not always the most important goal. For many people, avoiding pain and suffering and having a good death are more important (28).

Article Information

Acknowledgments

The author thanks her colleague, Professor Peter, for allowing her to adapt the information in Table 2 from their shared work. The author thanks Georgie Lee for her help with the reference list and manuscript submission. The author further acknowledges the people with diabetes at the end-of-life stage who have shared their experiences with her team.

Duality of Interest

No potential conflicts of interest relevant to this article were reported.

Author Contributions

T.L.D. is the sole author and guarantor of this work and takes responsibility for the integrity of the information presented.

  • © 2020 by the American Diabetes Association
https://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

References

  1. 1.↵
    1. Roper NA,
    2. Bilous RW,
    3. Kelly WF,
    4. Unwin NC,
    5. Connolly VM
    . Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389–1393
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Sharma A,
    2. Sikora L,
    3. Bush SH
    . Management of diabetes mellitus in adults at end of life: a review of recent literature and guidelines. J Palliat Med 2019;22:1133–1138
    OpenUrl
  3. 3.↵
    1. World Health Organization
    . The top 10 causes of death. Available from https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed December 2019
  4. 4.↵
    1. International Diabetes Federation
    . Global guideline for managing older people with type 2 diabetes. Available from https://www.idf.org/e-library/guidelines/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html. Accessed November 2019
  5. 5.↵
    1. Dunning T,
    2. Martin P
    . Guidelines for Deciding Palliative and End of Life Care With People with Diabetes. Available from https://www.caresearch.com.au/caresearch/Portals/0/Documents/PROFESSIONAL-GROUPS/General-Practitioners/Barwon-Health-guidelines-for-end-of-life-care-with-people-with-diabetes-2019.pdf. Accessed May 2020
  6. 6.↵
    1. Kalra S,
    2. Sharma SK
    . Diabetes in the elderly. Diabetes Ther 2018;9:493–500
    OpenUrl
  7. 7.
    1. Schiøtz ML,
    2. Høst D,
    3. Christensen MB, et al
    . Quality of care for people with multimorbidity: a case series. BMC Health Serv Res 2017;17:745
    OpenUrl
  8. 8.↵
    1. American Association of Clinical Endocrinologists
    . Management of common comorbidities of diabetes. Available from https://www.aace.com/disease-state-resources/diabetes/depth-information/management-common-comorbidities-diabetes. Accessed December 2019
  9. 9.↵
    1. Arnold SV,
    2. Lipska KJ,
    3. Wang J,
    4. Seman L,
    5. Mehta SN,
    6. Kosiborod M
    . Use of intensive glycemia management in older adults with diabetes mellitus. J Am Geriatr Soc 2018;66:1190–1194
    OpenUrl
  10. 10.↵
    1. Phillips JL,
    2. Currow DC
    . Cancer as a chronic disease. Collegian 2010;17:47–50
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    1. Murtagh FE,
    2. Preston M,
    3. Higginson I
    . Patterns of dying: palliative care for non-malignant disease. Clin Med (Lond) 2004;4:39–44
    OpenUrlPubMed
  12. 12.↵
    1. Dunning T
    . The common disease trajectories: are they relevant to guide care as older people with diabetes progress towards end of life? SM Gerontol Geriatr Res 2018;2:1011
    OpenUrl
  13. 13.↵
    1. Munshi MN,
    2. Florez H,
    3. Huang ES, et al
    . Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American Diabetes Association. Diabetes Care 2016;39:308–318
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. General Medical Council
    . Treatment and care towards the end of life: good practice in decision making. Available from https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/treatment-and-care-towards-the-end-of-life. Accessed May 2020
  15. 15.↵
    Caresearch. Care of the dying person. Available from https://www.caresearch.com.au/caresearch/tabid/738/Default.aspx. Accessed October 2019
  16. 16.↵
    1. Hippocrates
    . The Book of Prognostics. Adams F, Translator. Available from https://classics.mit.edu/Hippocrates/prognost.html. Accessed November 2019
  17. 17.↵
    1. Aslakson RA,
    2. Wyskiel R,
    3. Thornton I, et al
    . Nurse-perceived barriers to effective communication regarding prognosis and optimal end-of-life care for surgical ICU patients: a qualitative exploration. J Palliat Med 2012;15:910–915
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Worldwide Palliative Care Alliance, World Health Organization
    . WHO Global Atlas of Palliative Care at the End of Life. Available from https://www.thewhpca.org/resources/global-atlas-on-end-of-life-care. Accessed November 2019
  19. 19.↵
    1. World Health Organization
    . Strengthening of palliative care as a component of integrated treatment throughout the life course. J Pain Palliat Care Pharmacother2014;28:130–134
    OpenUrlPubMed
  20. 20.↵
    1. National Coalition for Hospice and Palliative Care
    . Clinical Practice Guidelines for Quality Palliative Care. 4th ed. Richmond, VA, National Coalition for Hospice and Palliative Care, 2018
  21. 21.↵
    1. Scott IA,
    2. Mitchell GK,
    3. Reymond EJ,
    4. Daly MP
    . Difficult but necessary conversations: the case for advance care planning. Med J Aust 2013;199:662–666
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Swerissen H,
    2. Duckett S
    . Dying Well. Available from https://grattan.edu.au/wp-content/uploads/2014/09/815-dying-well.pdf. Accessed May 2020
  23. 23.↵
    1. Diabetes UK
    . End of Life Diabetes Care Clinical Care Recommendations. 3rd ed. Available from https://www.diabetes.org.uk/resources-s3/2018-03/EoL_Guidance_2018_Final.pdf. Accessed November 2019
  24. 24.↵
    1. Foody JM
    . Insulin-induced hypoglycaemia and mortality after acute MI. Available from https://www.medscape.com/viewarticle/703980. Accessed January 2020
  25. 25.↵
    1. Krinsley JS
    . Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 2008;36:3008–3013
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. James J
    . Dying well with diabetes. Ann Palliat Med 2019;8:178–189
    OpenUrl
  27. 27.↵
    1. Savage S,
    2. Duggan N,
    3. Dunning T,
    4. Martin P
    . The experiences and care preferences of people with diabetes at the end of life: a qualitative study. J Hosp Palliat Nurs 2012;14:293–302
    OpenUrl
  28. 28.↵
    1. Milnes S,
    2. Corke C,
    3. Orford NR,
    4. Bailey M,
    5. Savulescu J,
    6. Wilkinson D
    . Patient values informing medical treatment: a pilot community and advance care planning survey. BMJ Support Palliat Care 2019;9:e23
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Chang EM,
    2. Gillespie EF,
    3. Shaverdian N
    . Truthfulness in patient-reported outcomes: factors affecting patients’ responses and impact on data quality. Patient Relat Outcome Meas 2019;10:171–186
    OpenUrl
  30. 30.↵
    1. Victoria State Government
    . The Medical Treatment Planning and Decisions Act 2016. Melbourne, Australia, Victoria State Government, 2016
  31. 31.↵
    1. Claessen SJ,
    2. Francke AL,
    3. Engels Y,
    4. Deliens L
    . How do GPs identify a need for palliative care in their patients? An interview study. BMC Fam Pract 2013;14:42
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Jäderling G,
    2. Bell M,
    3. Martling C-R,
    4. Ekbom A,
    5. Konrad D
    . Limitations of medical treatment among patients attended by the rapid response team. Acta Anaesthesiol Scand 2013;57:1268–1274
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Hancock K,
    2. Clayton JM,
    3. Parker SM, et al
    . Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review. Palliat Med 2007;21:507–517
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Dikkers MF,
    2. Dunning T,
    3. Savage S
    . Information needs of family carers of people with diabetes at the end of life: a literature review. J Palliat Med 2013;16:1617–1623
    OpenUrl
  35. 35.↵
    1. Yourman LC,
    2. Lee SJ,
    3. Schonberg MA,
    4. Widera EW,
    5. Smith AK
    . Prognostic indices for older adults: a systematic review. JAMA 2012;307:182–192
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. University of Edinburgh
    . Supportive and Palliative Care Indicators Tool (SPICT). Available from https://www.spict.org.uk/the-spict. Accessed December 2019
  37. 37.↵
    1. Framework GS
    . Proactive Identification Guidance Registration Form. Available from www.goldstandardsframework.org.uk/PIG. Accessed May 2020
  38. 38.↵
    1. Dunning T,
    2. Martin P,
    3. Duggan N,
    4. Savage S.
    The McKellar way: how to use The McKellar Guidelines for Managing Older People with Diabetes in Residential and Other Care Settings. Available from https://adma.org.au/download/the-mckellar-guidelines. Accessed May 2020
  39. 39.↵
    1. Hesse M,
    2. Forstmeier S,
    3. Ates G,
    4. Radbruch L
    . Patients’ priorities in a reminiscence and legacy intervention in palliative care. Palliat Care Soc Pract 2019;13:2632352419892629
    OpenUrl
  40. 40.
    1. Roikjær SG,
    2. Missel M,
    3. Bergenholtz HM,
    4. Schønau MN,
    5. Timm HU
    . The use of personal narratives in hospital-based care interventions: an integrative literature review. Palliat Med 2019;33:1255–1271
    OpenUrl
  41. 41.
    1. Iglay K,
    2. Hannachi H,
    3. Howie P, et al
    . Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1243–1252
    OpenUrlCrossRefPubMed
  42. 42.
    1. Bauduceau B,
    2. Le Floch J-P,
    3. Halimi S,
    4. Verny C,
    5. Doucet J; SFD/SFGG Intergroup
    . Cardiovascular complications over 5 years and their association with survival in GERODIAB cohort of elderly French patients with type 2 diabetes. Diabetes Care 2018;41:156–162
    OpenUrlAbstract/FREE Full Text
  43. 43.
    1. Tu H,
    2. Wen CP,
    3. Tsai SP, et al
    . Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ 2018;360:k134
    OpenUrlAbstract/FREE Full Text
  44. 44.
    1. Jyrkkä J,
    2. Enlund H,
    3. Korhonen MJ,
    4. Sulkava R,
    5. Hartikainen S
    . Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging 2009;26:493–503
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.
    1. Matlow JN,
    2. Bronskill SE,
    3. Gruneir A, et al
    . Use of medications of questionable benefit at the end of life in nursing home resident with advanced dementia. J Am Geriatr Soc 2017;65:1535–1542
    OpenUrl
  46. 46.
    1. Muche J,
    2. Kishner S
    . Geriatric rehabilitation. Available from https://emedicine.medscape.com/article/318521-overview. Accessed January 2020
  47. 47.
    1. Feinkohl L,
    2. Aung P,
    3. Keller M, et al.; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators
    . Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2014;37:507–515
    OpenUrlAbstract/FREE Full Text
  48. 48.
    1. Abdelhafiz AH,
    2. Rodríguez-Mañas L,
    3. Morley JE,
    4. Sinclair AJ
    . Hypoglycemia in older people: a less well recognized risk factor for frailty. Aging Dis 2015;6:156–167
    OpenUrlPubMed
  49. 49.
    1. Cacioppo JT,
    2. Cacioppo S
    . The growing problem of loneliness. Lancet 2018;391:426
    OpenUrl
  50. 50.
    1. Cohen-Mansfield J,
    2. Perach R
    . Interventions for alleviating loneliness among older persons: a critical review. Am J Health Promot 2015;29:e109–e125
    OpenUrlCrossRefPubMed
  51. 51.
    1. Pasqualini S,
    2. Barisic M,
    3. Serris C,
    4. Percheur R
    . Poor dental health and crushed drugs in nursing homes. J Nurs Home Res Sci 2019;5:76–79
    OpenUrl
  52. 52.
    1. Castro-Rodríguez M,
    2. Carnicero JA,
    3. Garcia-Garcia FJ, et al
    . Frailty as a major factor in the increased risk of death and disability in older people with diabetes. J Am Med Dir Assoc 2016;17:949–955
    OpenUrl
PreviousNext
Back to top
Diabetes Spectrum: 33 (3)

In this Issue

August 2020, 33(3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Spectrum.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Palliative and End-of-Life Care: Vital Aspects of Holistic Diabetes Care of Older People With Diabetes
(Your Name) has forwarded a page to you from Diabetes Spectrum
(Your Name) thought you would like to see this page from the Diabetes Spectrum web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Palliative and End-of-Life Care: Vital Aspects of Holistic Diabetes Care of Older People With Diabetes
Trisha Lynette Dunning
Diabetes Spectrum Aug 2020, 33 (3) 246-254; DOI: 10.2337/ds20-0014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Palliative and End-of-Life Care: Vital Aspects of Holistic Diabetes Care of Older People With Diabetes
Trisha Lynette Dunning
Diabetes Spectrum Aug 2020, 33 (3) 246-254; DOI: 10.2337/ds20-0014
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Palliative, Terminal, and End-of Life Care
    • Managing Diabetes During Transition to End of Life
    • Advance Care Planning
    • What Do People With Diabetes and Their Families Think?
    • Summary
    • Article Information
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Management of Diabetes Across the Life Spectrum
  • About Medha N. Munshi, MD: Guest Editor, Management of Diabetes Across the Life Spectrum
  • Challenges and Strategies for Managing Diabetes in the Elderly in Long-Term Care Settings
Show more From Research to Practice

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Clinical Diabetes
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Spectrum Print ISSN: 1040-9165, Online ISSN: 1944-7353.